Avita Medical Limited (RCEL) Launches Cohealyx

AVITA Medical, Inc. (NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and initial clinical utilization, an integrated wound bed was seen as early as 7 days.

Cohealyx expands AVITA Medical’s therapeutic wound care portfolio, complementing its flagship product, the RECELL® System, which is FDA-approved for the treatment of thermal burns and full-thickness skin defects, and PermeaDerm®, a temporary biosynthetic dressing used to support healing before and after grafting. These products support the two-stage standard of care for full-thickness wounds. Cohealyx is used as a dermal matrix to manage the wound bed. RECELL Spray-On Skin™ Cells and wound protection with PermeaDerm provide solutions for definitive closure. This integrated approach may improve clinical outcomes and expands AVITA Medical’s market opportunity.

“When treating full-thickness acute wounds in a two-stage procedure, a shorter time to graft readiness translates to a shorter hospital stay for the patient,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “During our pre-clinical validated porcine model study, wounds treated with Cohealyx were consistently graft-ready faster than the leading competitors used as controls. This treatment regimen has the potential to deliver faster healing and shorter hospital stays, consistent with the benefits of our flagship RECELL System and our overall mission.”

AVITA Medical is currently enrolling participants in the Cohealyx I trial, a post-market study designed to further evaluate clinical outcomes, wound bed preparation for definitive closure, and patient recovery timelines when Cohealyx is used in the management of full-thickness wounds. The Cohealyx I trial underscores AVITA Medical’s commitment to generating robust clinical data supporting the benefits and cost-effectiveness of its products.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• RenovoRx regains Nasdaq minimum bid price compliance
• Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters